Announcing product milestones and liking LinkedIn posts are just some of the topics addressed in a long-awaited guidance that deals with the challenges prescription drug makers face in the UK when using social media.
Liking a LinkedIn post, recruiting participants for clinical trials, disseminating corporate news and announcing product or pipeline milestones. These are among the topics covered by a first-of-its-kind UK guidance that aims to help pharmaceutical companies that manufacture prescription drugs navigate the potential pitfalls of social media.
The Social Media Guidance 2023 was published by the Prescription Medicines Code of Practice Authority, the independent body that administers...
Despite pushback by industry, the government is standing by its new statutory scheme rebate rates for branded medicines, including one that doubles the rate that companies must repay on the sales of newer products to the National Health Service to 31.3%.
EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.
The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.
